biostudies-literatureUnknown38(2)Koskinas J<h4>Background</h4>Newer advances involving immunotherapies are changing the hepatocellular carcinoma (HCC) landscape. In the multinational OPAL study, we described the characteristics of patients with HCC during 2014-2021 in Greece.<h4>Methods</h4>This was a retrospective chart review study of adults (alive/dead) with newly diagnosed HCC between 2014-2021.<h4>Results</h4>Of 406 patients, 37.7%, 33.0%, 25.9% and 3.4% had Barcelona Clinic Liver Cancer (BCLC) stage 0/A, B, C and D, respectively. Common etiologies were hepatitis B virus (32.9%), alcohol use (31.6%), hepatitis C virus (27.6%), and metabolic dysfunction-associated steatotic liver disease (26.3%); viral+non-viral: 15.5%. The first treatment was resection, embolization, ablation, systemic therapy and transplant, in 35.5%, 30.7%, Annals of gastroenterology195-207https://www.ebi.ac.uk/biostudies/studies/S-EPMC11928893biostudies-literatureTreatment patterns and outcomes in hepatocellular carcinoma: Real-world experience in Greece from the retrospective OPAL study.PMC11928893Alexopoulou APapagiouvanni IManolakopoulos SGoulis IDrygiannakis IKoskinas JKoutroubakis IMichailidou EMagafouraki EElefsiniotis IPapatheodoridis GKoullias EDeutsch MKranidioti HPantzios SSamonakis DTsaliki EfalseTreatment patterns and outcomes in hepatocellular carcinoma: Real-world experience in Greece from the retrospective OPAL study.<h4>Background</h4>Newer advances involving immunotherapies are changing the hepatocellular carcinoma (HCC) landscape. In the multinational OPAL study, we described the characteristics of patients with HCC during 2014-2021 in Greece.<h4>Methods</h4>This was a retrospective chart review study of adults (alive/dead) with newly diagnosed HCC between 2014-2021.<h4>Results</h4>Of 406 patients, 37.7%, 33.0%, 25.9% and 3.4% had Barcelona Clinic Liver Cancer (BCLC) stage 0/A, B, C and D, respectively. Common etiologies were hepatitis B virus (32.9%), alcohol use (31.6%), hepatitis C virus (27.6%), and metabolic dysfunction-associated steatotic liver disease (26.3%); viral+non-viral: 15.5%. The first treatment was resection, embolization, ablation, systemic therapy and transplant, in 35.5%, 30.7%, 2025-01-01T00:00:00Z2025 Mar-Apr2025-07-11T03:03:58.966Z2025-07-11T03:03:58.966ZS-EPMC119288934012443310.20524/aog.2025.0950